These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 844905)

  • 21. Experimental studies on cholera immunization. 4. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity.
    Svennerholm AM
    Int Arch Allergy Appl Immunol; 1975; 49(4):434-52. PubMed ID: 808500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A one dose experimental cholera vaccine.
    Muse M; Grandjean C; Wade TK; Wade WF
    FEMS Immunol Med Microbiol; 2012 Oct; 66(1):98-115. PubMed ID: 22612159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody responses in rabbits to injections of whole cell, flagella, and flagellin preparations of cholera and noncholera vibrios.
    Smith HL
    Appl Microbiol; 1974 Feb; 27(2):375-8. PubMed ID: 4823423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular cloning and expression in Escherichia coli K-12 of the O antigens of the Inaba and Ogawa serotypes of the Vibrio cholerae O1 lipopolysaccharides and their potential for vaccine development.
    Manning PA; Heuzenroeder MW; Yeadon J; Leavesley DI; Reeves PR; Rowley D
    Infect Immun; 1986 Aug; 53(2):272-7. PubMed ID: 2426198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Passive protection of mice against intraperitoneally injected Vibrio cholerae by G and M antibody.
    Pike RM; Chandler CH
    Infect Immun; 1971 Nov; 4(5):589-92. PubMed ID: 5154896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of fluorescent antibody in studies of immunity to cholera in infant mice.
    Guentzel MN; Field LH; Eubanks ER; Berry LJ
    Infect Immun; 1977 Feb; 15(2):539-48. PubMed ID: 321353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoglobulins in bile and serum of the rabbit associated with protection after Vibrio cholerae infection and vaccination.
    Rijpkema SG; Jansen WH; Gielen H; Guinée PA
    Microb Pathog; 1987 Nov; 3(5):365-75. PubMed ID: 2462153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunity in experimental cholera: effect of parenteral immunization with vaccines and toxoid.
    Sinha VB; Bhaskaran K
    Bull World Health Organ; 1973; 49(6):605-13. PubMed ID: 4548387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisera to selected outer membrane proteins of Vibrio cholerae protect against challenge with homologous and heterologous strains of V. cholerae.
    Das M; Chopra AK; Cantu JM; Peterson JW
    FEMS Immunol Med Microbiol; 1998 Dec; 22(4):303-8. PubMed ID: 9879921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and protective efficacy of Vibrio cholerae outer membrane vesicles in rabbit model.
    Roy N; Barman S; Ghosh A; Pal A; Chakraborty K; Das SS; Saha DR; Yamasaki S; Koley H
    FEMS Immunol Med Microbiol; 2010 Oct; 60(1):18-27. PubMed ID: 20528929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A monoclonal antibody that targets the conserved core/lipid A region of lipopolysaccharide affects motility and reduces intestinal colonization of both classical and El Tor Vibrio cholerae biotypes.
    Levinson KJ; Baranova DE; Mantis NJ
    Vaccine; 2016 Nov; 34(48):5833-5836. PubMed ID: 27773473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative analysis of the major protective antigens production in Vibrio cholerae recombinant and producer strains of the classical biovar].
    Toporkov AV; Zadnova SP; Smirnova NI
    Zh Mikrobiol Epidemiol Immunobiol; 2005; (1):53-7. PubMed ID: 15773401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection against mortality due to Vibrio cholerae infection in infant rabbits caused by immunization of mothers with cholera protective antigen.
    Sciortino CV
    J Diarrhoeal Dis Res; 1996 Mar; 14(1):16-26. PubMed ID: 8708328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo.
    Apter FM; Michetti P; Winner LS; Mack JA; Mekalanos JJ; Neutra MR
    Infect Immun; 1993 Dec; 61(12):5279-85. PubMed ID: 8225601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cumulative protective efficacy of rZot and rAce combination in challenge experiments with wild type Vibrio cholerae in mouse model.
    Anvari S; Najar-Peerayeh S; Behmanesh M; Bakhshi B
    Hum Vaccin Immunother; 2018; 14(9):2323-2328. PubMed ID: 29852089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the phenol-induced flagellar agglutination test for the identification of the cholera group of vibrios.
    Pastoris MC; Bhattacharyya FK; Sil J
    J Med Microbiol; 1980 May; 13(2):362-7. PubMed ID: 7381922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108.
    Liang W; Wang S; Yu F; Zhang L; Qi G; Liu Y; Gao S; Kan B
    Infect Immun; 2003 Oct; 71(10):5498-504. PubMed ID: 14500467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designing and Expression of Recombinant Chimeric Protein Containing CtxB and OmpW from Vibrio Cholerae and Evaluation of Its Immunogenicity.
    Vakili A; Mousavi Gargari SL; Nazarian S; Amani J
    Iran J Immunol; 2018 Sep; 15(3):207-220. PubMed ID: 30246696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
    Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
    Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.